Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib
Details
Publication Year 2025-02,Volume 66,Issue #1,Page 32-35
Journal Title
Australasian Journal of Dermatology
Publication Type
Case report
Abstract
Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
Keywords
Humans; Female; Aged; *Pyrazines/therapeutic use; *Benzamides/therapeutic use; Remission Induction; Carbamates/therapeutic use; Waldenstrom Macroglobulinemia/drug therapy; Protein Kinase Inhibitors/therapeutic use; Sneddon Wilkinson disease; acalabrutinib; monoclonal gammopathy of undetermined significance; subcorneal pustular dermatoses
Department(s)
Surgical Oncology; Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-12-10 02:43:10
Last Modified: 2025-03-14 07:08:01

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙